Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Shares Shorted: Short Interest Down 99.8% in October

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the recipient of a significant decrease in short interest during the month of October. As of October 30th, there was short interest totaling 1 shares, a decrease of 99.8% from the October 15th total of 580 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 2,297 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on MOLN. Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research report on Friday, October 2nd. HC Wainwright reiterated a “buy” rating on shares of Molecular Partners in a report on Monday, November 2nd. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Molecular Partners has a consensus rating of “Hold” and an average target price of $8.38.

Molecular Partners Trading Down 2.9%

Shares of MOLN traded down $0.09 during mid-day trading on Thursday, hitting $3.00. The company’s stock had a trading volume of 694 shares, compared to its average volume of 4,217. The company’s 50-day moving average is $3.84 and its 200-day moving average is $4.14. Molecular Partners has a 52-week low of $3.00 and a 52-week high of $5.36. The firm has a market capitalization of $121.12 million, a price-to-earnings ratio of -1.79 and a beta of 1.17.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings data on Thursday, October 29th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.08. As a group, sell-side analysts predict that Molecular Partners will post -1.22 earnings per share for the current fiscal year.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways. Molecular Partners’ research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.